ArticleInvestigational new drugs2024

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.

Maxime Chénard-Poirier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.